Update on multi-gene panel testing and communication of genetic test results.


Journal

The breast journal
ISSN: 1524-4741
Titre abrégé: Breast J
Pays: United States
ID NLM: 9505539

Informations de publication

Date de publication:
08 2020
Historique:
received: 08 11 2019
accepted: 14 11 2019
pubmed: 9 7 2020
medline: 22 6 2021
entrez: 9 7 2020
Statut: ppublish

Résumé

With technological advances, multi-gene panel testing has become increasingly used to identify patients at risk for hereditary breast cancer (HBC). There are currently evidence-based interventions and breast cancer screening strategies that exist for cancer prevention and early detection among patients with HBC. Moreover, in addition to the personal impact of identifying HBC, this information may be shared with at-risk family members to amplify the benefits of testing and subsequent care among those at high risk. Opportunities and challenges with the utilization of updated multi-gene panel testing for HBC, including: (a) tumor sequencing with germline consequences; (b) genetic counseling implications; and (c) strategies to improve the communication of genetic test results to family members will be reviewed. With the advances and expansion of genetic testing, all health care providers need to be updated on both the importance and complexities of HBC counseling and testing, in order to optimize patient care.

Identifiants

pubmed: 32639074
doi: 10.1111/tbj.13971
pmc: PMC7484453
mid: NIHMS1617550
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1513-1519

Subventions

Organisme : NCI NIH HHS
ID : K12 CA090625
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA160056
Pays : United States

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Ann Clin Lab Sci. 2009 Fall;39(4):331-7
pubmed: 19880759
Int J Epidemiol. 2020 Feb 1;49(1):216-232
pubmed: 31605532
J Clin Oncol. 2007 Apr 10;25(11):1329-33
pubmed: 17416853
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
JAMA Oncol. 2017 Dec 1;3(12):1654-1662
pubmed: 28472234
Am Soc Clin Oncol Educ Book. 2019 Jan;39:61-74
pubmed: 31099663
Nat Genet. 2008 Jan;40(1):17-22
pubmed: 18163131
J Natl Compr Canc Netw. 2014 Sep;12(9):1339-46
pubmed: 25190699
Ann Surg Oncol. 2017 Oct;24(10):3060-3066
pubmed: 28766213
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Expert Rev Anticancer Ther. 2019 Sep;19(9):787-801
pubmed: 31469018
J Clin Oncol. 2017 Dec 1;35(34):3800-3806
pubmed: 28820644
Cancer. 2016 Dec 1;122(23):3673-3681
pubmed: 27496084
J Oncol Pract. 2019 Sep;15(9):474-475
pubmed: 31509717
Front Biosci (Landmark Ed). 2013 Jun 01;18:1358-72
pubmed: 23747889
Nat Rev Clin Oncol. 2016 Sep;13(9):581-8
pubmed: 27296296
J Genet Couns. 2017 Feb;26(1):173-181
pubmed: 27422778
Genet Med. 2018 Feb;20(2):234-239
pubmed: 28749474
JAMA Oncol. 2016 Jan;2(1):104-11
pubmed: 26556299
Psychooncology. 2018 Jul;27(7):1825-1832
pubmed: 29645321
JAMA Oncol. 2017 Sep 1;3(9):1190-1196
pubmed: 28418444
J Oncol Pract. 2019 Sep;15(9):465-473
pubmed: 31509718
JAMA Surg. 2018 Dec 1;153(12):1145-1146
pubmed: 30167656
JAMA. 2010 Sep 1;304(9):967-75
pubmed: 20810374
Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2211-9
pubmed: 20699375
Sci Transl Med. 2015 Apr 15;7(283):283ra53
pubmed: 25877891
Genet Med. 2019 Jul;21(7):1497-1506
pubmed: 30504931
Fam Cancer. 2018 Oct;17(4):471-483
pubmed: 28918466
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Nat Rev Clin Oncol. 2019 Jun;16(6):386-396
pubmed: 30783251
J Clin Oncol. 2017 Jul 10;35(20):2240-2250
pubmed: 28448241
J Clin Oncol. 2019 Feb 20;37(6):453-460
pubmed: 30526229
JAMA. 2017 Sep 5;318(9):825-835
pubmed: 28873162
JAMA. 2018 Sep 25;320(12):1266-1274
pubmed: 30264118
N Engl J Med. 2015 Jun 4;372(23):2243-57
pubmed: 26014596
Fam Cancer. 2005;4(2):115-9
pubmed: 15951961
J Pers Med. 2019 Mar 01;9(1):
pubmed: 30832243
Ann Oncol. 2016 May;27(5):795-800
pubmed: 26787237
J Clin Oncol. 2011 Oct 1;29(28):3747-52
pubmed: 21876083
Nat Genet. 2018 Sep;50(9):1219-1224
pubmed: 30104762
Am J Hum Genet. 1998 Mar;62(3):676-89
pubmed: 9497246
J Clin Oncol. 2015 Nov 1;33(31):3660-7
pubmed: 26324357
Curr Genomics. 2010 May;11(3):146-61
pubmed: 21037853
Genet Test. 2008 Mar;12(1):81-91
pubmed: 18373407
J Health Commun. 2017 Feb;22(2):143-152
pubmed: 28112991
Expert Rev Mol Diagn. 2017 Jan;17(1):57-70
pubmed: 27910721
Curr Oncol Rep. 2014 Mar;16(3):371
pubmed: 24488544
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Genet Med. 2017 Feb;19(2):249-255
pubmed: 27854360

Auteurs

Sonya Reid (S)

Vanderbilt University Medical Center, Nashville, Tennessee.

Tuya Pal (T)

Vanderbilt University Medical Center, Nashville, Tennessee.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH